angiotensin receptor

L162389 is an orally active and potent angiotensin II receptor antagonist with a balanced affinity for AT1 and AT2 receptor subtypes that stimulates the conversion of phosphatidylinositol.

Losartan potassium (DuP-753 potassium), an Angiotensin II Receptor Blocker, selectively and competitively inhibits the binding of angiotensin II to the angiotensin I (AT1) receptor.

Losartan (DuP-753) is an angiotensin II receptor antagonist.

Azilsartan (TAK-536) is an Angiotensin 2 Receptor Blocker that acts as an Angiotensin 2 Type 1 Receptor Antagonist, leading to a physiologic effect of decreased blood pressure.

Olmesartan Medoxomil (Benicar) is an angiotensin II type 1 receptor blocker that is used to manage hypertension.

Telmisartan (BIBR 277) is an Angiotensin 2 Receptor Blocker. The mechanism of action of telmisartan is as an Angiotensin 2 Receptor Antagonist.

Irbesartan (SR-47436) is an Angiotensin 2 Receptor Blocker whose mechanism of action involves antagonizing the Angiotensin 2 Receptor.

Trans-Tranilast is an antiallergic drug developed by Kissei Pharmaceuticals. It was approved in 1982 for use in Japan and South Korea for bronchial asthma. Indications for keloid and hypertrophic scar were added in 1993. It has been used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis.

Sacubitril/Valsartan (LCZ696) is an orally bioavailable, dual angiotensin II receptor and neprilysin inhibitor for the treatment of hypertension and heart failure.

Candesartan Cilexetil (TCV-116) is an angiotensin II receptor antagonist (IC50: 0.26 nM). Upon hydrolysis to candesartan during gastrointestinal absorption, it selectively competes with angiotensin II for binding to the angiotensin II receptor subtype 1 (AT1) in vascular smooth muscle, blocking angiotensin II-mediated vasoconstriction and inducing vasodilatation.

Eprosartan Mesylate (SKF-108566J) is a competitive and reversible Angiotensin II Receptor Blocker.

Tranilast (SB 252218), an antiallergic drug, suppresses lipid mediator and cytokine release from inflammatory cells, therefore utilized in the treatment of allergic disorders.

Olmesartan (RNH 6270) is an Angiotensin II Type I receptor antagonist. Olmesartan is the active form of the antihypertensive drug olmesartan medoxomil,and has antihypertensive activity.

Azilsartan Medoxomil (TAK-491) is an orally administered angiotensin II receptor type 1 antagonist with IC50 of 0.62 nM, which used in the treatment of adults with essential hypertension.

Valsartan (CGP 48933) is a tetrazole derivative and angiotensin II type 1 receptor blocker that is used to treat hypertension.

Zabicipril is a novel orally available angiotensin-converting enzyme inhibitor, a prodrug with antihypertensive activity following in vivo de-esterification.

YS-49 is an activator of PI3K/Akt (a downstream target of RhoA).

ZD 7155 hydrochloride is an angiotensin II receptor type 1 (AT1 receptor) antagonist.

Candesartan (CV 11974) is an angiotensin II receptor blocker widely used in the treatment of hypertension and heart failure.

Nitrosoglutathione (GSNO) is an endogenous transnitrosation donor involved in S-nitrosation of a variety of cellular proteins. GSNO, an exogenous NO donor and substrate of rat alcohol dehydrogenase class III isoenzyme, inhibits cerebral angiotensin II-dependent and -independent AT1 receptor responses.

Angiotensin 1/2 (5-7) acetate is a peptide with the sequence H2N-Ile-His-Pro-OH. Angiotensin is an oligopeptide and is a hormone and a powerful dipsogen. It is derived from the precursor molecule angiotensinogen, a serum globulin produced in the liver. It

Fimasartan (BR-A-657) is a non-peptide angiotensin II receptor antagonist (ARB) used for the treatment of hypertension and heart failure. Concurrent administration of fimasartan with diuretic hydrochlorothiazide has shown to be safe in clinical trials.

BIBS 39 is a novel nonpeptide angiotensin II (AII) receptor antagonist.

Losartan Carboxylic Acid (E-3174), a potent AT1 antagonist (Kis: 0.57 nM, rat; 0.67 nM, human), produces a depressor response and vasodilatation. As a metabolite of losartan, it is more potent than losartan in blocking angiotensin II-induced responses in vascular smooth muscle cells.